Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Period	Debt/Equity
2019-12-31	2.19
2020-12-31	0.20
2021-12-31	0.72
2022-12-31	0.67
2023-12-31	0.54
2024-12-31	0.43

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARCT	$8.46	-0.59%	0.52M
3
4
5

Arcturus Therapeutics Holdings Inc. (ARCT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Arcturus Therapeutics Holdings Inc. Data in Excel

More ARCT Financial Data